ABSTRACT

23
Adgrg6 (Gpr126) is an adhesion class G protein-coupled receptor with a conserved role in 24 myelination of the peripheral nervous system. In the zebrafish, mutation of adgrg6 also 25 results in defects in the inner ear: otic tissue fails to down-regulate versican-gene expression 26 and morphogenesis is disrupted. We have designed a whole-animal screen that tests for Adgrg6 (Gpr126) is an adhesion (B2) class G protein-coupled receptor (aGPCR) with 38 conserved roles in myelination of the vertebrate peripheral nervous system (PNS) (reviewed 39 in (Langenhan et al., 2016; Patra et al., 2014) ). In homozygous loss-of-function adgrg6 40 zebrafish and mouse mutants, peripheral myelination is severely impaired: Schwann cells 41 associate with axons, but are unable to generate the myelin sheath, and show reduced 42 expression of the myelin basic protein (mbp) gene (Glenn and Talbot, 2013; Mogha et al., 43 2013; Monk et al., 2009; Monk et al., 2011) . Targeted disruption of Adgrg6 in the mouse 44 results in additional abnormal phenotypes, including limb and cardiac abnormalities, axon 45 degeneration and embryonic lethality (Monk et al., 2011; Patra et al., 2014; Waller-Evans et 46 al., 2010) . In humans, mutations in ADGRG6 are causative for congenital contracture 47 syndrome 9, a severe type of arthrogryposis multiplex congenita (Ravenscroft et al., 2015) . 48 Peripheral nerves from affected individuals have reduced expression of myelin basic protein, 49 suggesting that the function of ADGRG6 in myelination is evolutionarily conserved from 50 teleosts to humans (Ravenscroft et al., 2015) . Human ADGRG6 variants have also been 51 proposed to underlie some paediatric musculoskeletal disorders, including adolescent 52 idiopathic scoliosis (Karner et al., 2015) (and references within). In zebrafish, homozygous loss-of-function adgrg6 mutants exhibit an inner ear defect in 55 addition to deficiencies in myelination (Geng et al., 2013; Monk et al., 2009 ). In the otic 56 vesicle, the epithelial projections that prefigure formation of the semicircular canal ducts 57 overgrow and fail to fuse, resulting in morphological defects and ear swelling. Analysis of 58 the zebrafish adgrg6 mutant ear shows a dramatic alteration in the expression of genes 59 coding for several extracellular matrix (ECM) components and ECM-modifying enzymes 60 (Geng et al., 2013) (Fig. 1A) . Notably, transcripts coding for core proteins of the chondroitin 61 sulphate proteoglycan Versican, normally transiently expressed in the outgrowing 62 projections and then down-regulated once projection fusion has occurred, remain highly 63 expressed in the overgrown and unfused projections of adgrg6 mutants (Geng et al., 2013) . 64 Although Adgrg6 (Gpr126) mRNA is known to be expressed in the mouse ear (Patra et al., 65 2013), a role in otic development in the mammal has yet to be determined. Like all aGPCR members, the zebrafish Adgrg6 receptor consists of a long extracellular 68 domain (ECD), a seven-pass transmembrane domain (7TM), and a short intracellular 69 domain (reviewed in (Langenhan et al., 2016) ) (Fig. 1B) . The ECD includes a GPCR 70 autoproteolysis-inducing (GAIN) domain, which incorporates the GPCR proteolytic site 71 (GPS) and the conserved Stachel sequence (Liebscher et al., 2014; Patra et al., 2014) . 72 Proteolysis at the GPS results in two fragments, an NTF (N-terminal fragment) and a CTF 73 (C-terminal fragment), which can remain associated with one another, or may dissociate, the 74 NTF binding to cell surface or extracellular matrix ligands (Patra et al., 2014; Petersen et al., 75 2015) . Dissociation of the NTF triggers binding of the Stachel sequence to the 7TM domain, 76 thereby activating the CTF (Liebscher et al., 2014) . This feature provides a variety of CTF-77 dependent or -independent signalling capabilities that orchestrate cell adhesion and other 78 cell-cell or cell-matrix interactions. For example, during Schwann cell development and 79 terminal differentiation, the Adgrg6 NTF promotes radial sorting of axons, while the CTF is 80 thought to signal through a stimulatory Ga subunit (Gas), leading to elevated cAMP levels 81 and activated protein kinase A (PKA) to induce transcription of downstream target genes, 82 such as egr2 and oct6 (Petersen et al., 2015) . Compounds that act to raise intracellular 83 cAMP levels, such as the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX) 84 and the adenylyl cyclase activator forskolin, can rescue phenotypic defects in both the inner 85 ear and PNS in adgrg6 mutants (Geng et al., 2013; Monk et al., 2009). 86 87 Despite the enormous importance of GPCRs as drug targets (Hauser et al., 2017; Sriram 88 and Insel, 2018; Wootten et al., 2018) , adhesion class GPCRs remain poorly characterised, 89 representing a valuable untapped resource as targets of future therapeutics (Hamann et al., 90 2015; Monk et al., 2015) . The identification of specific modulators of aGPCR activity is an 91 essential step for understanding the mechanism of aGPCR function and to inform the design 92 of new drugs. Recent successful approaches include the use of Stachel sequence peptides 93 as aGPCR agonists (Demberg et al., 2017) , or synthetic monobodies directed against 94 domains within the NTF (Salzman et al., 2017) . A promising alternative approach lies in the 95 potential of unbiased whole-animal screening of small molecules. In recent years, zebrafish 96 have emerged as an important tool for in vivo phenotypic screening for new therapeutics 97 (Brady et al., 2016) and for understanding biological mechanisms (Baxendale et al., 2017;  98 Richter et al., 2017) . Zebrafish have many advantages for drug discovery: they are a 99 vertebrate species whose embryos can fit into individual wells of a multiwell plate, facilitating 100 high-throughput analysis; they generate large numbers of offspring; they can absorb 101 compounds directly added to the water, and whole-organism screening enables toxicity, 102 absorption, metabolism and excretion of compounds to be assayed early in the screening 103 pipeline.
105
To date, over one hundred drug screens using different zebrafish disease models have been 106 conducted, some identifying lead compounds that have subsequently been tested in 107 mammalian model systems or entered clinical trials (Chowdhury et al., 2013; Griffin et al., 108 2017; North et al., 2007; Owens et al., 2008 ) (reviewed in (Baxendale et al., 2017) ). Two 109 screens have been performed to identify compounds that promote myelination in the central 110 nervous system (Buckley et al., 2010; Early et al., 2018 reproducible assay that can be semi-automated (Baxendale et al., 2012; North et al., 2007) .
148
We selected vcanb expression in the adgrg6 mutant ear for our primary screen. We first made a careful comparison of the otic and PNS defects in weak (tb233c) and strong 160 (fr24) alleles for the adgrg6 mutant (Fig. 1A) . The tb233c allele is a missense mutation 161 (I963N) in the fourth transmembrane domain of the receptor, whereas the fr24 allele is a 162 nonsense mutation (L463X), predicting a severely truncated protein lacking the GAIN, 7TM 163 and C-terminal domains (Geng et al., 2013) (Fig. 1B) hours post fertilisation (hpf), but is then strongly down-regulated after fusion; by 4 days post 173 fertilisation (dpf), very little expression is detectable in the ear (Geng et al., 2013) . By 174 contrast, in adgrg6 mutants, the overgrown and unfused projections in the developing ear 175 continue to express vcanb at high levels (Geng et al., 2013) (Fig. 1A) . Both alleles show a 176 dramatically increased level of expression over wild-type embryos, but the increase is 177 stronger in the fr24 allele (Fig. 1A) . mRNA for adgrg6 itself is expressed in mutant embryos 178 for both alleles (Geng et al., 2013) (and unpublished data) .
180
In addition to an upregulation of vcanb expression in the ear, the zebrafish adgrg6 mutant 181 also shows a reduction or loss of expression of the myelin basic protein (mbp) gene in the 182 PNS (Geng et al., 2013; Monk et al., 2009 (Geng et al., 2013) . At this stage of development, the anterior and 219 posterior projections in the mutant otic vesicle are extended and in close proximity to the 220 lateral projection, to which they would fuse in the wild type ( Fig. 2A) nine of these compounds was reduced; however, for seven compounds, the scores between 338 the two libraries remained significantly different. These discrepancies could be either due to 339 differences in compound purity between the two suppliers, or could be due to experimental Table S1 ). we chose two groups for further analysis ( Fig. 4G ; boxes at 300, 2500). These groups with 394 five or more compounds included the pyridines (cluster 1 on the scatter plot) and the 395 tetranortriterpenoids (gedunin derivatives) (cluster 2 on the scatter plot). The pyridine 396 cluster included one pyrazolopyridine and six dihydropyridines, a class of L-type calcium 397 channel blockers with vasodilatory properties (reviewed in (Tocci et al., 2018) antineoplastic and neuroprotective effects (Jang et al., 2010; Subramani et al., 2017) . 400 401 Data from each of the screens and retests were used to cluster the compounds into groups 402 based on their activity (displayed as a heat map in Fig. 5A ), and compared with a compound 403 network display based on structural similarity in Fig. 5B The four compounds shown in Figure 6 were also selected for dose-response assessment, and is a known activator of adenylyl cyclase, supporting this interpretation (Fig. 8) alleles between the two classes can be seen in Figure 8C . Relatively few zebrafish screens have been undertaken to identify compounds that can 519 increase myelination (Buckley et al., 2010; Early et al., 2018) or restore myelination in 520 neuropathy models (Zada et al., 2016) It is of interest to note that one of the main groups of compounds identified as potential 601 interactors of the receptor in the fr24 screen is a cluster of gedunin derivatives (cluster 2).
602
One of these compounds, deoxygedunin, has previously been identified as a TrkB agonist 603 that has neuroprotective properties (Nie et al., 2015) , can promote axon regeneration after 604 nerve injury (English et al., 2013) , and, interestingly, has been found to protect the vestibular 605 ganglion from degeneration in mice mutant for BDNF (Jang et al., 2010 The flavonoids are a group of molecules with wide ranging activities, including anti-cancer 628 and neuroprotective properties (reviewed in (Braidy et al., 2017) 
MATERIALS AND METHODS
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Animals
665
Standard zebrafish husbandry methods were employed (Westerfield, 2000 (Geng et al., 2013; Whitfield et al., 1996) , and were raised 672 on a pigmented background. In all cases shown, mutant embryos are homozygous for the 673 respective allele. The transgenic strain used for imaging in Fig. 1 were given to drugs that showed an ability to down-regulate vcanb expression to some For the mbp counter screen (Fig. 4D,E Chemical structures of the library compounds represented as SMILES (Weininger, 1988) 914 mutant ear (score 3). Scores 2 (Aii) and 1 (Aiii) were given to embryos that showed reduced vcanb 915 mRNA expression to some extent, with 1 given for a stronger down-regulation than 2. (Aiv) Score 0 916 was given to embryos where vcanb mRNA levels were equivalent to wild-type levels. B. Compounds 917 were categorised A-G according to the total vcanb score from the three embryos treated. Colours for 918 each category correspond to the colours used in panels C- to the category A-G they were assigned to after the primary screen, with jitter (noise) introduced to 936 improve visualisation. C. Polar scatter plot of the 91 hit compounds that passed the first retest and 937 were followed up with mbp counter screens; previous scores for the compounds not followed are 938 faded. D-G. mbp scoring system and classification of the compounds. D. Scoring system used to 939 assess mbp mRNA expression levels in the PLLg of adgrg6 tb233c embryos after treatment. (Di) A 940 score of 3 was given to embryos where mbp mRNA expression was similar to wild-type levels. Black 941 arrowhead: mbp expression in PLLg; asterisks mark expression near the three cristae of the ear. (Dii) 942 A score of 2 was given to embryos that showed mbp expression in the PLLg, but this was weaker 943 than 3. (Diii) A score of 1 was given to embryos with mbp expression identical to the one seen in 944 untreated adgrg6 tb233c mutants (absence of mbp expression in PLLg; white arrowhead). (Div) A score 945 of 0 was used to indicate embryos where mbp mRNA expression was absent from the PLLg, but also 946 reduced from the Schwann cells of the posterior and anterior lateral line. E. Compounds were 947 categorised according to the mbp score from six embryos (average of the total score from three 948 embryos) and grouped into compounds able to rescue mbp expression (score >3.5-9) and unable to 949 rescue mbp expression (>1.5-3.5). A third class of compounds down-regulated both vcanb and mbp 950 (score 0-1.5) and were not followed further. F. Distribution of the compounds in the different rescue 951 categories after the mbp counter screen. G. Polar scatter plot of the final 68 hit compounds (non-952 faded) after mbp counter screens. Bigger dots represent compounds that rescued mbp expression, 953 whereas smaller dots correspond to the compounds that did not rescue mbp expression; compounds 954 that downregulated mbp expression, or were not followed, are faded. Wedges on the scatter plot 955 delineate the two clusters of compounds with similar structures for which some hits were followed up 956 in further analysis (see text). The positions of IBMX (I) and colforsin (C) are indicated (red 957 arrowheads). nodes. The colours used for compounds/nodes correspond to categories A-G (as indicated in Figure  973 3) and the two clusters of structurally similar compounds highlighted in Figure 4 are also shown here. 1  1  2  1  1  3  3  2  3  3  1  3  3  3   5  S04  B02  IVERMECTIN  antiparasitic  2  2  2  1  0  0  0  0  0  2  2  1  3  3  3  3  3  3   6  T01  F06  SC-10  protein kinase C activator, NMDA  receptor activator  2  2  2  2  2  1  2  2  2  3  3  3  2  1  1  3  3  3   7  T01  H11  1,3-DIPROPYL-8-PHENYLXANTHINE  Selective adenosine A1 receptor  antagonist  2  2  1  0  0  0  2  2  1  3  3  2  2  2  1  3  3  3   8  S17  E02  3-DEOXO-3BETA-ACETOXYDEOXYDIHYDROGEDUNIN  undetermined  0  0  0  0  0  0  0  0  0  3  3  1  2  2  2  3  3  3   9  T11  F07  CILNIDIPINE  dihydropyridine N-and L-type  Ca 2+ channel blocker  0  0  0  1  1  1  1  1  1  3  2  2  2  2  2  3  3  3   10  S13  F03  AMIODARONE HYDROCHLORIDE  coronary vasodilator, Ca 2+  channel blocker  1  1  1  2  2  2  2  2  2  3  3  3  2  2  0  3  3  3   11  S06  E02  HYDROCORTISONE  HEMISUCCINATE  glucocorticoid  1  1  1  1  0  0  3  2  2  1  1  1  3  3  3  3  3  3   12  T01  C04  (RS)-(TETRAZOL-5-YL) GLYCINE  highly potent NMDA receptor  agonist  2  1  1  0  0  0  2  2  1  2  2  2  2  1  1  3  3  3   13  S02  E05  LOMEFLOXACIN HYDROCHLORIDE  antibacterial  1  1  1  3  2  1  3  2  2  1  1  1  3  2  2  3  3  3   14  S13  E04  ETHAMIVAN  CNS & respiratory stimulant  1  1  1  2  2  1  2  2  2  2  1  1  2  2  2  3  3  3   15  T08  B04  CGS 15943  potent adenosine receptor  antagonist  2  2  2  2  2  2  2  1  1  1  1  1  2  2  2  3  3  3   16  S13  E09  ASTEMIZOLE  H1 antihistamine (nonsedating)  1  1  1  2  1  1  3  2  2  1  1  1  2  2  2  3  3  3   17  T02  A09  SKF 91488 DIHYDROCHLORIDE  histamine N-methyltransferase  inhibitor  2  1  1  0  0  0  2  2  1  2  2  1  1  1  1  3  3  3   18  S25  F05   11ALPHA-HYDROXYPROGESTERONE  HEMISUCCINATE   glucocorticoid  1  1  1  0  0  0  2  2  1  1  1  1  2  2  1  3  3  3   19  T14  A07  EFONIDIPINE HYDROCHLORIDE  MONOETHANOLATE   dihydropyridine L-type and T-type  Ca 2+ channel blocker  1  1  1  1  0  0  3  2  2  2  2  1  1  1  1  3  3  3   20  T05  C09  NIFEDIPINE  dihydropyridine L-type  Ca 2+ channel blocker  1  1  1  2  1  1  2  2  2  3  3  3  2  2  1  3  3  2 21  T05  E08  CGP 37157  antagonist of mitochondrial  Na + /Ca 2+ exchange  1  1  1  2  2  2  1  1  0  3  3  3  2  1  1  3  3  2   22  S05  D03  DANAZOL  anterior pituitary suppressant,  anti-estrogenic  0  0  0  1  0  0  2  0  0  2  2  1  2  2  1  3  3  2   23  S18  H09  XANTHYLETIN  undetermined  0  0  0  0  0  0  1  1  1  2  2  1  2  1  1  3  3  2   24  S18  A06  FERULIC 0  0  0  0  0  0  0  0  0  3  3  3  3  3  3  0  0  0   33  T04  G02  IMILOXAN HYDROCHLORIDE  selective α2B-adrenoceptor  antagonist.  0  0  0  1  1  0  ND  ND  ND  3  3  3  ND  ND  ND  ND  ND  ND   34  S24  C03  3ALPHA-ACETOXYDIHYDRODEOXYGEDUNIN  undetermined  0  0  0  1  0  0  0  0  0  3  3  3  3  3  2  DE  DE  DE   35  S11  E02  EZETIMIBE  antihyperlipidemic (sterol  absorption inhibitor)  0  0  0  2  2  2  0  0  0  3  3  3  2  2  2  0  0  0   36  S10  E06  NITRENDIPINE  dihydropyridine L-type  Ca 2+ channel blocker  1  1  1  0  0  0  1  0  0  3  2  2  ND  ND  ND  ND  ND  ND   37  S11  E08  ROSUVASTATIN CALCIUM  antihyperlipidemic  0  0  0  0  0  0  0  0  0  2  1  1  3  3  2  0  0  0   38  S22  C07  DEMETHYLNOBILETIN  undetermined  0  0  0  0  0  0  0  0  0  2  2  2  2  2  2  0  0  0   39  S22  G11  HEXAMETHYLQUERCETAGETIN  undetermined  0  0  0  0  0  0  0  0  0  2  2  1  2 E10  CARBIMAZOLE  antithyroid  1  1  1  2  2  1  3  3  2  1  1  1  1  1  1  3  3  2   57  T07  D03  CGP 7930  positive modulator at  GABAB receptors  1  1  1  2  1  1  3  3  2  1  1  1  1  1  1  3  3  2   58  T02  D07  METHIOTHEPIN MALEATE  potent 5-HT2 and 5-HT1 antagonist  0  0  0  0  0  0  1  1  1  DE  DE  DE  1  1  1  3  3  2   59  T02  A11  GBR 12935 DIHYDROCHLORIDE  selective inhibitor of dopamine  uptake  2  2  1  0  0  0  3  3  1  1  1  1  2  1  1  3  3  3   60  S25  A06  CHOLIC ACID  undetermined  1  1  1  0  0  0  3  2  2  1  1  1  2  1  1  3  3  3   61  S16  F04  MANNITOL  diuretic, sweetener, diagnostic aid  1  1  1  2  2  2  2  2  2  1  1  1  2  1  1  3  3  3   62  S11  H04  DECOQUINATE  coccidiostat  1  1  1  0  0  0  2  2  2  1  1  1  1  1  1  3  3  3   63  S17  C06   3-DEOXO-3BETA-HYDROXYMEXICANOLIDE 16-ENOL  ETHER   undetermined  0  0  0  0  0  0  2  2  2  1  1  1  1  1  1  3  3  3   64  T05  H11  DL-TBOA  non-transportable blocker of  excitatory amino acid transporters  2  2  2  2  2  2  2  2  2  DE  DE  DE  1  1  1  3  3  3   65  T12  D09  SD 208  potent ATP-competitive TGF-βRI  inhibitor  1  1  1  1  1  1  2  1  1  1  1  1  1  1  1  3  3  3   66  S18  C08  HARMINE  antiparkinsonian, CNS stimulant  1  1  1  2  2  2  2  1  1  1  1  1  1  1  1  3  3  3   67  S18  D03  7-DESHYDROXYPYROGALLIN-4-CARBOXYLIC ACID  undetermined  1  1  1  0  0  0  2  1  1  1  1  1  1  1  1  3  3  3   68  T07  C09  TMS  cytochrome P450 1B1 inhibitor  0  0  0  0  0  0  2  2  2  1  1  0  1  1  1  3  3  3 69  S19  F06  LARIXOL ACETATE  potent TRPC6 Inhibitor*  0  0  0  1  1  2  3  3  3  0  0  0  0  0  1  3  3  3   70  S02  C03  ECONAZOLE NITRATE  antifungal  0  0  0  0  0  0  2  2  2 *Deoxygedunin: (Jang et al., 2010) ; Nobiletin: ; Angolensin (R): (Weisman et al., 2006) ; Sinensetin: (Kang et al., 2015) ; Larixol acetate: (Urban et al., 2016) ; Gedunin: (Hieronymus et al., 2006; Subramani et al., 2017) .
